Literature DB >> 19726515

Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus.

Desyreé Murta Jesus1, Lilian T Costa, Daniela L Gonçalves, Carlos Alberto Achete, Marcia Attias, Nissin Moussatché, Clarissa R Damaso.   

Abstract

Cidofovir (CDV) is one of the most effective antiorthopoxvirus drugs, and it is widely accepted that viral DNA replication is the main target of its activity. In the present study, we report a detailed analysis of CDV effects on the replicative cycles of distinct vaccinia virus (VACV) strains: Cantagalo virus, VACV-IOC, and VACV-WR. We show that despite the approximately 90% inhibition of production of virus progeny, virus DNA accumulation was reduced only 30%, and late gene expression and genome resolution were unaltered. The level of proteolytic cleavage of the major core proteins was diminished in CDV-treated cells. Electron microscopic analysis of virus-infected cells in the presence of CDV revealed reductions as great as 3.5-fold in the number of mature forms of virus particles, along with a 3.2-fold increase in the number of spherical immature particles. A detailed analysis of purified virions recovered from CDV-treated cells demonstrated the accumulation of unprocessed p4a and p4b and nearly 67% inhibition of DNA encapsidation. However, these effects of CDV on virus morphogenesis resulted from a primary effect on virus DNA synthesis, which led to later defects in genome encapsidation and virus assembly. Analysis of virus DNA by atomic force microscopy revealed that viral cytoplasmic DNA synthesized in the presence of CDV had an altered structure, forming aggregates with increased strand overlapping not observed in the absence of the drug. These aberrant DNA aggregations were not encapsidated into virus particles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726515      PMCID: PMC2772695          DOI: 10.1128/JVI.01061-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Atomic force microscopy of DNA molecules stretched by spin-coating technique.

Authors:  J Y Ye; K Umemura; M Ishikawa; R Kuroda
Journal:  Anal Biochem       Date:  2000-05-15       Impact factor: 3.365

Review 2.  The acyclic nucleoside phosphonates from inception to clinical use: historical perspective.

Authors:  Erik De Clercq
Journal:  Antiviral Res       Date:  2006-11-07       Impact factor: 5.970

3.  A PCR-based assay for detection of emerging vaccinia-like viruses isolated in Brazil.

Authors:  Clarissa R A Damaso; Sheila A Reis; Desyreé M Jesus; Patrícia S F Lima; Nissin Moussatché
Journal:  Diagn Microbiol Infect Dis       Date:  2006-09-01       Impact factor: 2.803

4.  In vitro activity of cidofovir against the emerging Cantagalo virus and the smallpox vaccine strain IOC.

Authors:  Desyreé Murta Jesus; Nissin Moussatché; Clarissa R Damaso
Journal:  Int J Antimicrob Agents       Date:  2008-09-19       Impact factor: 5.283

5.  Herpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation.

Authors:  A K Sheaffer; W W Newcomb; M Gao; D Yu; S K Weller; J C Brown; D J Tenney
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 6.  When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond.

Authors:  Nissin Moussatché; Clarissa R Damaso; Grant McFadden
Journal:  J Infect Dev Ctries       Date:  2008-06-01       Impact factor: 0.968

7.  An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine.

Authors:  C R Damaso; J J Esposito; R C Condit; N Moussatché
Journal:  Virology       Date:  2000-11-25       Impact factor: 3.616

8.  Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand.

Authors:  Wendy C Magee; Kathy A Aldern; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

9.  Isolation and characterization of cidofovir resistant vaccinia viruses.

Authors:  Marie N Becker; Maria Obraztsova; Earl R Kern; Debra C Quenelle; Kathy A Keith; Mark N Prichard; Ming Luo; Richard W Moyer
Journal:  Virol J       Date:  2008-05-14       Impact factor: 4.099

10.  Severe eczema vaccinatum in a household contact of a smallpox vaccinee.

Authors:  Surabhi Vora; Inger Damon; Vincent Fulginiti; Stephen G Weber; Madelyn Kahana; Sarah L Stein; Susan I Gerber; Sylvia Garcia-Houchins; Edith Lederman; Dennis Hruby; Limone Collins; Dorothy Scott; Kenneth Thompson; John V Barson; Russell Regnery; Christine Hughes; Robert S Daum; Yu Li; Hui Zhao; Scott Smith; Zach Braden; Kevin Karem; Victoria Olson; Whitni Davidson; Giliane Trindade; Tove Bolken; Robert Jordan; Debbie Tien; John Marcinak
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 20.999

View more
  11 in total

1.  Solution structure of a DNA duplex containing the potent anti-poxvirus agent cidofovir.

Authors:  Olivier Julien; James R Beadle; Wendy C Magee; Subhrangsu Chatterjee; Karl Y Hostetler; David H Evans; Brian D Sykes
Journal:  J Am Chem Soc       Date:  2011-01-31       Impact factor: 15.419

2.  Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells.

Authors:  Garth D Tylden; Hans H Hirsch; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

3.  Vaccinia Virus B1 Kinase Is Required for Postreplicative Stages of the Viral Life Cycle in a BAF-Independent Manner in U2OS Cells.

Authors:  Augusta Jamin; Nouhou Ibrahim; April Wicklund; Kaitlin Weskamp; Matthew S Wiebe
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

4.  Tricyclo[3.2.2.0(2,4)]non-8-en-6,7-dicarbonic acid derivatives efficiently inhibits the replication of different orthopoxvirus species.

Authors:  B A Selivanov; E F Belanov; N I Bormotov; S M Balakhnin; O A Serova; V A Svyatchenko; N N Kiselev; E I Kazachinskaya; V B Loktev; A Ya Tikhonov
Journal:  Dokl Biol Sci       Date:  2012-01-07

Review 5.  Orthopoxvirus targets for the development of new antiviral agents.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Antiviral Res       Date:  2012-03-08       Impact factor: 10.103

6.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

Review 7.  Drug Development against Smallpox: Present and Future.

Authors:  Déborah Delaune; Frédéric Iseni
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.938

8.  SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral.

Authors:  Anna C T C Pereira; Jamária A P Soares-Martins; Flávia G G Leite; André F P Da Cruz; Alice A Torres; Thais Souto-Padrón; Erna G Kroon; Paulo C P Ferreira; Cláudio A Bonjardim
Journal:  Antiviral Res       Date:  2011-11-02       Impact factor: 5.970

Review 9.  Why do poxviruses still matter?

Authors:  Zhilong Yang; Mark Gray; Lake Winter
Journal:  Cell Biosci       Date:  2021-05-22       Impact factor: 7.133

Review 10.  Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.

Authors:  Aarthi Narayanan; Charles Bailey; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.